What Springhood does

Springhood is a Boston-based venture capital firm founded in 2017 by John Parker that provides seed-stage equity capital to startups developing clinical solutions for children. The firm positions itself as the first venture capital investor broadly focused on children's health, targeting areas such as neonatal care, pediatric oncology, rare disease diagnostics, developmental disorders, and other pediatric indications. Springhood's business model combines an impact-first mission with a stated pursuit of commercial returns, arguing that pediatric markets benefit from regulatory incentives, smaller and faster clinical trials, FDA/legislative prioritization of pediatrics, and government mandates expanding Medicaid and public health programs. Capital is deployed through its direct investment vehicle, Springhood Impact Capital, LLC, at the seed stage. The firm does not disclose its fund size, AUM, or management fee structure; its public-facing deal-sourcing channel is a website-based Airtable submission form for prospective portfolio companies.

The firm's investment activity and thought leadership rest on a defined thesis: that generalist investors systematically underweight child health due to perceived small market size, slow regulatory paths, and ethical trial complexity, and that this bias creates a structural opportunity for a focused, knowledgeable investor. Springhood's competitive position is anchored in founder John Parker's 25 years of alternative investment experience combined with a decade of philanthropy, and his concurrent role as a Trustee of the Charles H. Hood Foundation and Founder/Managing Director of CH Innovations, LLC, a child health venture fund wholly owned by the Foundation. Springhood LLC is a separate legal entity from CH Innovations, with no disclosed financial relationship between the two portfolios. Springhood's publicly disclosed portfolio includes Neopredics, TMA Precision Health, and Kamali Therapeutics; CH Innovations' portfolio includes Nicolette, Mesentech, Prapela, Inkspace Imaging, Argus Cognitive, MMIB Health, Stingray Tx, and Neopenda.

As a micro-VC with 1-10 employees, Springhood operates with a lean team structure centered on a single principal. Revenue derives from management fees and potential carried interest on deployed capital, but no fund AUM, LP composition, or revenue figures are publicly disclosed. The firm has not announced any funding rounds for its management company, acquisitions, geographic expansions, or material leadership additions beyond the founder.

Name

Springhood

Legal name

Springhood LLC

Website

https://www.springhood.com/

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Springhood is a Boston-based seed-stage venture capital firm founded in 2017 that invests in startups developing clinical solutions for children, including neonatal care, pediatric oncology, rare disease, and developmental disorders, through its direct investment vehicle Springhood Impact Capital, LLC.

Ownership category

akta.pro rank

Product category

Venture Capital (Child Health Impact Investing)

NAICS

Open-End Investment Funds (525910)

SIC

Investment Advice (6282)

akta.pro primary industry

Early-Stage Venture Capital (Pre-Seed/Seed) (FSANAAAA)

akta.pro secondary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

Keywords

• Venture capital investing
• Child health investment
• Seed stage funding
• Pediatric healthcare
• Impact investing

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels1 record

Core offering

Springhood is a venture capital firm that provides vital early-stage (seed) capital to startups developing clinical solutions that significantly improve health outcomes for children. Through its direct investment vehicle, Springhood Impact Capital, LLC, the firm backs young companies with strong science and clear commercial pathways in areas such as neonatal care, pediatric oncology, rare disease diagnostics, and developmental disorders. Springhood combines a mission-first impact approach with commercial viability, providing both capital and resources to help child health entrepreneurs navigate the startup journey.

Product overview

Springhood is a venture capital firm providing early-stage investment and support to child health-focused startups. It operates through its direct investment vehicle, Springhood Impact Capital, LLC, which focuses on seed-stage companies developing clinical solutions for children. The firm offers investment capital, resources, and strategic support to help entrepreneurs navigate the startup journey. Companies seeking investment can submit their decks through the Springhood platform via Airtable integration. Springhood's model combines mission-first impact investing with commercial viability, targeting companies with strong science, clear commercial pathways, and significant potential to improve pediatric health outcomes.

Differentiator

Problem solved

Functional benefit

Products and services

• Springhood Impact Capital, LLC

Quantifiable outcome

• Reducing rare disease diagnostic journey from 7 years to 3 months (portfolio company TMA Precision Health)

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• OrbiMed: OrbiMed is one of the largest healthcare-dedicated investment firms, with venture, growth, and credit strategies spanning biopharma, medtech, and diagnostics. It is comparable to Springhood as a healthcare-focused capital provider but operates at far greater scale and is not vertically specialized in pediatrics.
• RA Capital Management: RA Capital is a healthcare-focused investment manager spanning private venture through public equities, with deep expertise in clinical and commercial diligence. Comparable to Springhood as healthcare-dedicated capital, though it operates across stages and is not pediatric-vertical.
• Andreessen Horowitz (a16z Bio): a16z Bio is a large generalist firm's dedicated bio/health fund investing across therapeutics, digital health, and diagnostics. Comparable to Springhood as an investor in early-stage health innovation, though much larger and not pediatric-specialized.
• Lux Capital: Lux Capital is an early-stage venture firm that invests in science and technology-driven companies, including health and biotech. Comparable to Springhood in early-stage, science-first orientation, but it operates across sectors and not pediatrics specifically.
• Khosla Ventures: Khosla Ventures is a large early-stage venture firm with significant healthcare and biotech investments alongside technology. Comparable to Springhood as a risk-tolerant early-stage health investor, though not pediatric-focused and far larger in scale.

Direct peers

• 5AM Ventures: 5AM Ventures is an early-stage venture firm focused on life sciences, investing at the company-creation and seed stages. Comparable to Springhood in stage and life-sciences focus, though it is not pediatric-specific.
• Atlas Venture: Atlas Venture is an early-stage life sciences venture firm that builds companies from inception around novel science. Comparable to Springhood in stage and science-driven thesis, though it spans therapeutic areas rather than specializing in children's health.
• Polaris Partners: Polaris Partners is a multi-stage venture firm with a substantial healthcare and life sciences franchise, including early-stage biotech and medtech investing. Comparable to Springhood as an early-stage healthcare investor, though its portfolio is broader than pediatrics.
• Section32: Section32 is a venture fund investing in healthcare and technology-enabled health companies, founded by a former Google Ventures partner. Comparable to Springhood as a dedicated health-focused early-stage investor, though broader in therapeutic scope.
• ARCH Venture Partners: ARCH is an early-stage venture firm focused on building companies from frontier science, including biotech and health technology. It is comparable to Springhood as a seed/early-stage investor in science-driven health ventures, although it is not pediatric-specific.

Market position

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Springhood